228 related articles for article (PubMed ID: 30577662)
1. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Lux MP; Nabieva N; Hartkopf AD; Huober J; Volz B; Taran FA; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Schneeweiss A; Brucker SY
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577662
[TBL] [Abstract][Full Text] [Related]
2. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Laakmann E; Emons J; Taran FA; Janni W; Uhrig S; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Schulmeyer C; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Volz B; Fasching PA; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Hartkopf AD
Geburtshilfe Frauenheilkd; 2020 Nov; 80(11):1134-1142. PubMed ID: 33173241
[No Abstract] [Full Text] [Related]
3. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Michel LL; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Volz B; Huebner H; Wimberger P; Hielscher C; Mundhenke C; Kurbacher C; Wuerstlein R; Untch M; Overkamp F; Huober J; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Schneeweiss A; Fehm TN
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080911
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer.
Mehta S; Xie J; Ionescu-Ittu R; Nie X; Kwong WJ
Oncol Ther; 2023 Dec; 11(4):481-493. PubMed ID: 37715853
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Wong DJ; Hurvitz SA
Ann Transl Med; 2014 Dec; 2(12):122. PubMed ID: 25568875
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
[TBL] [Abstract][Full Text] [Related]
14. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Pizzuti L; Krasniqi E; Sperduti I; Barba M; Gamucci T; Mauri M; Veltri EM; Meattini I; Berardi R; Di Lisa FS; Natoli C; Pistelli M; Iezzi L; Risi E; D'Ostilio N; Tomao S; Ficorella C; Cannita K; Riccardi F; Cassano A; Bria E; Fabbri MA; Mazzotta M; Barchiesi G; Botticelli A; D'Auria G; Ceribelli A; Michelotti A; Russo A; Salimbeni BT; Sarobba G; Giotta F; Paris I; Saltarelli R; Marinelli D; Corsi D; Capomolla EM; Sini V; Moscetti L; Mentuccia L; Tonini G; Raffaele M; Marchetti L; Minelli M; Ruggeri EM; Scavina P; Bacciu O; Salesi N; Livi L; Tinari N; Grassadonia A; Fedele Scinto A; Rossi R; Valerio MR; Landucci E; Stani S; Fratini B; Maugeri-Saccà M; De Tursi M; Maione A; Santini D; Orlandi A; Lorusso V; Cortesi E; Sanguineti G; Pinnarò P; Cappuzzo F; Landi L; Botti C; Tomao F; Cappelli S; Bon G; Pelle F; Cavicchi F; Fiorio E; Foglietta J; Scagnoli S; Marchetti P; Ciliberto G; Vici P
Ther Adv Med Oncol; 2021; 13():17588359211059873. PubMed ID: 35173816
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.
Fabi A; De Laurentiis M; Caruso M; Valle E; Moscetti L; Santini D; Cannita K; Carbognin L; Ciccarese M; Rossello R; Arpino G; Leonardi V; Montemurro F; La Verde N; Generali D; Zambelli A; Scandurra G; Russillo M; Paris I; D'Ottavio AM; Filippelli G; Giampaglia M; Stani S; Fabbri A; Alesini D; Cianniello D; Giannarelli D; Cognetti F
Oncotarget; 2017 Sep; 8(38):64481-64489. PubMed ID: 28969087
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States.
Denduluri N; Espirito JL; Hackshaw MD; Wentworth C; Recchia T; Kwong WJ
Drugs Real World Outcomes; 2023 Jun; 10(2):177-186. PubMed ID: 36539672
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Lu D; Burris HA; Wang B; Dees EC; Cortes J; Joshi A; Gupta M; Yi JH; Chu YW; Shih T; Fang L; Girish S
Curr Drug Metab; 2012 Sep; 13(7):911-22. PubMed ID: 22475266
[TBL] [Abstract][Full Text] [Related]
18. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
19. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
